{
    "id": "dbpedia_2334_0",
    "rank": 65,
    "data": {
        "url": "https://docs.google.com/spreadsheets/d/1tb2vO5d6volg9es595sXxRwwAygZwII8s1_A9zAMVHY",
        "read_more_link": "",
        "language": "en",
        "title": "Marihuana database (version 1.0) -- ClinicalTrials.gov and PubMed",
        "top_image": "https://lh7-us.googleusercontent.com/docs/AHkbwyL3SZVpFOUS5PSN1BWjfeGBQrQA9PkzMen2_Xk9VlfyFFrEtiJk2zkz8ObP86qlb7AhTXU74Lxnb2e8VPrmkXVym4ABI0Hj8PzC6pxLMQCsy4vgMsbK=w1200-h630-p",
        "meta_img": "https://lh7-us.googleusercontent.com/docs/AHkbwyL3SZVpFOUS5PSN1BWjfeGBQrQA9PkzMen2_Xk9VlfyFFrEtiJk2zkz8ObP86qlb7AhTXU74Lxnb2e8VPrmkXVym4ABI0Hj8PzC6pxLMQCsy4vgMsbK=w1200-h630-p",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "de",
        "meta_favicon": "//ssl.gstatic.com/docs/spreadsheets/spreadsheets_2023q4.ico",
        "meta_site_name": "Google Docs",
        "canonical_link": "https://docs.google.com/spreadsheets/d/1tb2vO5d6volg9es595sXxRwwAygZwII8s1_A9zAMVHY/edit?usp=embed_facebook",
        "text": "1\n\nRankNCT NumberTitleRecruitmentStudy ResultsConditionsInterventions\n\nSponsor/Collaborators\n\nGenderAge GroupsPhasesEnrollmentFunded BysStudy TypesStudy DesignsOther IDsFirst ReceivedStart DateCompletion DateLast UpdatedLast Verified\n\nResults First Received\n\nAcronym\n\nPrimary Completion Date\n\nOutcome Measures\n\nURL\n\n2\n\n1NCT00743366\n\nEffect of Quetiapine on Marijuana Withdrawal and Relapse\n\nCompleted\n\nNo Results Available\n\nMarijuana Smoking\n\nDrug: Marijuana|Drug: Quetiapine\n\nNew York State Psychiatric Institute|Research Foundation for Mental Hygiene, Inc. |National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 220Other|NIHInterventional\n\nEndpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)\n\n5685|5P50DA009236\n\nAugust 26, 2008August 2008March 2009February 4, 2013February 2013\n\nNo Study Results Posted\n\nnullMarch 2009\n\nMarijuana relapse|Marijuana Withdrawal\n\nhttp://ClinicalTrials.gov/show/NCT00743366\n\n3\n\n2NCT00373295\n\nEffect of Baclofen on Marijuana Withdrawal and Relapse\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Baclofen|Drug: Marijuana\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 213Other|NIHInterventional\n\nEndpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)\n\n5232|5P50DA009236\n\nSeptember 7, 2006\n\nMay 2006January 2010February 4, 2013February 2013\n\nNo Study Results Posted\n\nnullJanuary 2008\n\nmarijuana self-administration|marijuana withdrawal symptoms\n\nhttp://ClinicalTrials.gov/show/NCT00373295\n\n4\n\n3NCT00373503\n\nEffect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Lofexidine|Drug: dronabinol|Drug: Marijuana\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 28Other|NIHInterventional\n\nEndpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)\n\n4942|R01DA019239\n\nSeptember 7, 2006\n\nAugust 2005\n\nSeptember 2008\n\nFebruary 4, 2013February 2013\n\nNo Study Results Posted\n\nnullJune 2007\n\nmarijuana relapse|marijuana withdrawal symptoms\n\nhttp://ClinicalTrials.gov/show/NCT00373503\n\n5\n\n4NCT01109563\n\nTeen Marijuana Check-Up\n\nActive, not recruiting\n\nNo Results Available\n\nCannabis Use Disorder\n\nBehavioral: Marijuana Check-Ins|Behavioral: Educational Feedback Control\n\nDenise Walker|Virginia Polytechnic Institute and State University|University of Washington\n\nBothChild|AdultPhase 3250OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)\n\n37852-G|2R01DA014296-09A1\n\nApril 21, 2010March 2011\n\nSeptember 2014\n\nMay 20, 2014May 2014\n\nNo Study Results Posted\n\nnull\n\nSeptember 2014\n\nfrequency (number of days) of marijuana use|treatment utilization|marijuana abuse/dependence symptoms|engagement in cognitive behavioral skills training sessions|self-efficacy|normative perceptions of peer marijuana use\n\nhttp://ClinicalTrials.gov/show/NCT01109563\n\n6\n\n5NCT01323569\n\nAbuse Potential of Sativex\n\nCompleted\n\nNo Results Available\n\nEvaluation of Abuse Potential of Sativex\n\nDrug: Sativex|Drug: Sativex|Drug: Sativex|Drug: Placebo|Drug: Marinol|Drug: Marinol\n\nGW Pharmaceuticals Ltd.\n\nBothAdultPhase 158IndustryInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nGWCP0605March 23, 2011February 2008June 2008June 13, 2013June 2013\n\nNo Study Results Posted\n\nnullJune 2008\n\nComparison of Subjective Drug Value (SDV)(Balance of effects) between Marinol and Sativex|Comparison of Bipolar Drug Liking VAS (Balance of effects) between Marinol and Sativex|Comparison of Addiction Research Centre Inventory (ARCI) MBG (Positive effects) between Marinol and Sativex|Comparison of Balance of Effects VASs between Marinol and Sativex|Comparison of Positive Effects VASs between Marinol and Sativex|Comparison of Cannabinoid Effects between Marinol and Sativex|Comparison of Negative Effects Scores between Marinol and Sativex|Comparison of Other Effects Scores between Marinol and Sativex|Area under the concentration-time curve from 0 to 8.5 hours post-dose for plasma THC, CBD, and 11-hydroxy-THC.|Adverse Events\n\nhttp://ClinicalTrials.gov/show/NCT01323569\n\n7\n\n6NCT02177513\n\nEffects of Cannabis Administration Routes on Human Performance and Pharmacokinetics\n\nRecruiting\n\nNo Results Available\n\nCannabis Use\n\nDrug: Placebo + Placebo|Drug: Oral Cannabis + Placebo|Drug: Placebo + Inhaled Cannabis|Drug: Placebo + Smoked Cannabis|Drug: 6.9% cannabis oral\n\nNational Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)\n\nBothAdultPhase 180NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n999914135|14-DA-N135\n\nJune 24, 2014June 2014\n\nSeptember 2016\n\nAugust 27, 2014May 2014\n\nNo Study Results Posted\n\nnullJuly 2016\n\nCannabis' pharmacodynamic effects|Cannabis' pharmacokinetic profiles|Pharmacokinetic/Dynamic Modelling|Cannabis oral fluid cutoff evaluation|Cannabinoid stability in dried blood|Cannabinoid stability in oral fluid|Cannabis' effects on appetitive peptides|Cannabis urine cutoff evaluation|Compare on-site oral fluid devices\n\nhttp://ClinicalTrials.gov/show/NCT02177513\n\n8\n\n7NCT00893074\n\nThe Effect of Prescription Medications in Marijuana Users\n\nRecruiting\n\nNo Results Available\n\nMarijuana Abuse\n\nDrug: bupropion, diazepam, dronabinol, ramelteon (Investigational Drug)\n\nJohns Hopkins University|National Institute on Drug Abuse (NIDA)\n\nBothAdult|SeniorPhase 1|Phase 221Other|NIHInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Outcomes Assessor)\n\nNA_00026278|R01-DA025044\n\nApril 30, 2009April 2009October 2011July 15, 2011May 2009\n\nNo Study Results Posted\n\nnullOctober 2011\n\nmarijuana withdrawal|subjective effects of smoked marijuana|cognitive performance\n\nhttp://ClinicalTrials.gov/show/NCT00893074\n\n9\n\n8NCT00350285\n\nThe Teen Marijuana Check-Up\n\nCompleted\n\nNo Results Available\n\nCannabis Abuse|Cannabis Dependence\n\nBehavioral: Motivational enhancement therapy|Behavioral: Marijuana education\n\nUniversity of Washington|National Institute on Drug Abuse (NIDA)\n\nBothChild|AdultPhase 2310Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n01-8666-G-05|RO1 DA014296\n\nJuly 5, 2006\n\nSeptember 2004\n\nJune 2008\n\nOctober 21, 2008\n\nOctober 2008\n\nNo Study Results Posted\n\nTMCU3June 2008\n\nSelf-report of marijuana use|Accepting abstinence-focused counseling\n\nhttp://ClinicalTrials.gov/show/NCT00350285\n\n10\n\n9NCT01748799\n\nFixed or Self-Titrated Dosages of Sativex on Cannabis Users\n\nCompleted\n\nNo Results Available\n\nCannabis Dependence\n\nDrug: Sativex|Drug: Placebo spray\n\nCentre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR)\n\nBothAdult10OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)\n\n103/2011|243152\n\nDecember 8, 2012\n\nFebruary 2013\n\nSeptember 2014\n\nSeptember 5, 2014\n\nSeptember 2014\n\nNo Study Results Posted\n\nnull\n\nSeptember 2014\n\nFeasibility|Tolerability of Sativex in persons that are Cannabis dependent\n\nhttp://ClinicalTrials.gov/show/NCT01748799\n\n11\n\n10NCT00946348\n\nCannabis and Schizophrenia: Self-Medication and Agonist Treatment\n\nCompletedHas Results\n\nSchizophrenia|Dual Diagnosis|Schizoaffective Disorder|Psychotic Disorder|Cannabis Use Disorder\n\nDrug: Dronabinol|Drug: Cannabis\n\nDartmouth-Hitchcock Medical Center|National Institute on Drug Abuse (NIDA)|Indiana University|Columbia University|University of Vermont|University of Massachusetts, Worcester\n\nBothAdultPhase 112Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nR01 DA013196|1R01DA026799-01|R01DA013196|R01DA026799-01|DPMC\n\nJuly 24, 2009December 2009October 2012\n\nSeptember 26, 2014\n\nSeptember 2014\n\nApril 9, 2014nullOctober 2012\n\nfMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC).|To Assess the Effects of Dronabinol in This Population to Determine Whether Measures of Craving, Mood and Negative Symptoms Will Improve Using the PANSS; and to Determine Whether Measures of Psychotic Symptoms and Cognitive Deficits Will Increase.\n\nhttp://ClinicalTrials.gov/show/NCT00946348\n\n12\n\n11NCT01323465\n\nStudy to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex\n\nCompleted\n\nNo Results Available\n\nEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor.\n\nDrug: Sativex and rifampicin|Drug: Sativex and rifampicin|Drug: Sativex and ketoconazole|Drug: Sativex and ketoconazole|Drug: Sativex and omeprazole|Drug: Sativex and omeprazole\n\nGW Pharmaceuticals Ltd.\n\nMaleAdultPhase 136IndustryInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label\n\nGWCP0602March 23, 2011February 2008March 2008June 13, 2013June 2013\n\nNo Study Results Posted\n\nnullMarch 2008\n\nPharmacokinetic analysis - Cmax of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole|Pharmacokinetic analysis - AUC(0-t) of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole|Pharmacokinetic analysis - AUC(0-inf) of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole|Adverse Events\n\nhttp://ClinicalTrials.gov/show/NCT01323465\n\n13\n\n12NCT01964404\n\nCannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?\n\nRecruiting\n\nNo Results Available\n\nSchizophrenia|Dual Diagnosis|Psychotic Disorder|Cannabis Use Disorder\n\nDrug: Marijuana|Drug: Dronabinol|Drug: Placebo\n\nDartmouth-Hitchcock Medical Center|Columbia University|Harvard Medical School|Massachusetts Institute of Technology|Massachusetts General Hospital|Nathan Kline Institute for Psychiatric Research|University of Vermont\n\nBothAdultPhase 1240OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n1R01DA034699-01A1\n\nOctober 15, 2013\n\nJuly 2014April 2020\n\nSeptember 30, 2014\n\nSeptember 2014\n\nNo Study Results Posted\n\nnullApril 2019\n\nBrain Reward Circuit Activation|Resting State Connectivity\n\nhttp://ClinicalTrials.gov/show/NCT01964404\n\n14\n\n13NCT01798186\n\nPharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation\n\nCompleted\n\nNo Results Available\n\nCannabis Intoxication\n\nDrug: Cannabis|Drug: Second-hand cannabis smoke\n\nRyan Vandrey|Substance Abuse and Mental Health Services Administration (SAMHSA)|RTI International|Johns Hopkins University\n\nBothAdultPhase 1|Phase 238Other|U.S. FedInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label\n\nNA_00082269\n\nFebruary 18, 2013\n\nMay 2013August 2013\n\nDecember 3, 2013\n\nDecember 2013\n\nNo Study Results Posted\n\nnullAugust 2013\n\ndelta-9-tetrahydrocanabinol (THC) Tmax|Intoxication\n\nhttp://ClinicalTrials.gov/show/NCT01798186\n\n15\n\n14NCT01747850\n\nSativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence\n\nBehavioral: Motivational Enhancement/Cognitive Behavioral Therapy|Drug: Sativex|Drug: Placebo spray\n\nCentre for Addiction and Mental Health|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 245Other|NIHInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)\n\n144/2011|R21DA031906\n\nDecember 7, 2012\n\nMarch 2013December 2015June 26, 2014June 2014\n\nNo Study Results Posted\n\nnullApril 2015\n\nTolerability and efficacy of intervention|Days of cannabis use|Withdrawal|Cannabis Craving|Cannabis use\n\nhttp://ClinicalTrials.gov/show/NCT01747850\n\n16\n\n15NCT00580671\n\nTreatment for Adolescent Marijuana Abuse\n\nCompletedHas ResultsMarijuana Abuse\n\nBehavioral: MET/CBT|Behavioral: CM|Behavioral: BPT\n\nDartmouth-Hitchcock Medical Center|National Institutes of Health (NIH)\n\nBothChild|Adult153Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n75185|5R01DA015186-07|5R01DA015186-08\n\nDecember 21, 2007\n\nNovember 2007December 2013\n\nSeptember 16, 2014\n\nSeptember 2014\n\nMarch 25, 2013nullJuly 2012\n\nMarijuana Abstinence (2 Weeks or Greater)|Marijuana Abstinence (4 Weeks or Greater)|Proportion of Days of Marijuana Abstinence Across All Days of Treatment (14 Weeks)\n\nhttp://ClinicalTrials.gov/show/NCT00580671\n\n17\n\n16NCT01037088\n\nEffects of Vaporized Marijuana on Neuropathic Pain\n\nCompletedHas Results\n\nNeuropathic Pain|Reflex Sympathetic Dystrophy|Peripheral Neuropathy|Post-herpetic Neuralgia|Spinal Cord Injury|Multiple Sclerosis\n\nDrug: Cannabis|Drug: Cannabis|Drug: Cannabis\n\nUniversity of California, Davis|Center for Medicinal Cannabis Research|VA Northern California Health Care System\n\nBothAdult|SeniorPhase 1|Phase 244Other|U.S. FedInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\n200614658|C06-DA-119\n\nDecember 17, 2009\n\nDecember 2009November 2012April 5, 2013April 2013\n\nDecember 6, 2012\n\nnullNovember 2012\n\nParticipants With 30% or Greater Reduction in Pain Intensity\n\nhttp://ClinicalTrials.gov/show/NCT01037088\n\n18\n\n17NCT01875796\n\nIntegrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence|Anxiety Disorders\n\nBehavioral: Cognitive-Behavioral Therapy|Behavioral: Motivation Enhancement Therapy|Behavioral: Integrated Cannabis and Anxiety Reduction Treatment|Behavioral: False Safety Behavior Elimination Therapy\n\nLouisiana State University and A&M College|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 172Other|NIHInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)\n\nRDA031937A|1R34DA031937-01\n\nJune 10, 2013June 2013nullJune 10, 2013June 2013\n\nNo Study Results Posted\n\nnullJuly 2015\n\ncannabis use|cannabis-related problems|anxiety\n\nhttp://ClinicalTrials.gov/show/NCT01875796\n\n19\n\n18NCT01620177\n\nEffects of Inhaled Cannabis on Driving Performance\n\nCompleted\n\nNo Results Available\n\nAlcohol Drinking|Cannabis\n\nDrug: Alcohol(oral) and placebo|Drug: Cannabis(THC)(Inhaled) and Placebo\n\nUniversity of Iowa|NHTSA|National Institute on Drug Abuse (NIDA)\n\nBothAdult99Other|NIHInterventional\n\nAllocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\n201109850June 4, 2012July 2012March 2014April 25, 2014April 2014\n\nNo Study Results Posted\n\nnullMarch 2014\n\nDriving Performance|Rogers gambling task|Balloon Analogue Risk Task (BART)|Subjective effect-Good Drug Effect|THC concentration in plasma sample|THC concentration levels in Whole blood|Subjective effect-high|Subjective effect-Stoned|Subjective effect-Stimulated|Subjective effect-sedated|Subjective effect-anxious|Subjective effect-Restless|Subjective effect-difficulty concentrating|Subjective effect-Altered sense of time|Subjective effect-slowed speech|Subjective effect-body feels sluggish/heavy|Subjective effect-Feeling of hunger|Subjective effect-thirsty|Subjective effect-Shakiness|Subjective effect-nausea|Subjective effect-Headache|Subjective effect-Palpitations|Subjective effect-Upset stomach|Subjective Effect-Dizzy|Subjective Effect-Dry mouth/throat|THC concentration in Saliva\n\nhttp://ClinicalTrials.gov/show/NCT01620177\n\n20\n\n19NCT01983267\n\nEvaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.\n\nNot yet recruiting\n\nNo Results Available\n\n1- Cancer Patients During Chemotherapy Treatment|2- Use of Cannabis Comparing to Control Without Cannabis Use\n\nDrug: cannabis\n\nRambam Health Care Campus\n\nBothAdult|Senior100OtherInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label\n\nCannabis-related cog impair\n\nOctober 29, 2013\n\nNovember 2013December 2016\n\nNovember 6, 2013\n\nNovember 2013\n\nNo Study Results Posted\n\nnullDecember 2016\n\nCannabis effect on cognitive function during chemotherapy\n\nhttp://ClinicalTrials.gov/show/NCT01983267\n\n21\n\n20NCT01975688\n\nA Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis\n\nRecruiting\n\nNo Results Available\n\nHead and Neck Squamous Cell Carcinoma\n\nDrug: Sativex\n\nGW Pharmaceuticals Ltd.\n\nBothAdult|SeniorPhase 124IndustryInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nGWCP10115\n\nOctober 29, 2013\n\nJanuary 2014November 2015January 27, 2014January 2014\n\nNo Study Results Posted\n\nnullNovember 2014\n\nThe time to peak plasma concentration (Cmax) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex|Area under the concentration-time curve from administration until the last sampling point (t) equal or above the Lower Limit of Quantification (AUC(0-t)) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex|Area under the concentration-time curve extrapolated to infinity (AUC(0-∞)) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex|Median time to maximum plasma concentration (Tmax) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex|Terminal half-life (t1/2) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex|Apparent total body clearance of drug from plasma (CL/F) of THC, 11-hydroxy-THC, CBD, 7-hydroxy-CBD and 6-hydroxy-CBD after a single dose of Sativex|The incidence of adverse events as a measure of subject safety\n\nhttp://ClinicalTrials.gov/show/NCT01975688\n\n22\n\n21NCT00613405\n\nStress and Marijuana Cue-elicited Craving and Reactivity\n\nCompletedHas Results\n\nCannabis Use Disorders\n\nOther: Stress + cue exposure|Other: No stress + cue exposure\n\nMedical University of South Carolina|National Institute on Drug Abuse (NIDA)\n\nBothAdult87Other|NIHInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label\n\nHR#17195|R21DA022424|R21-DA022424-01A1\n\nFebruary 11, 2008\n\nJanuary 2008May 2009April 23, 2013April 2013June 15, 2011nullMay 2009\n\nSubjective Craving of Marijuana|Physiological Assessments: Serum Cortisol, ACTH, BP, HR, and GSR|Feelings of Stress/Anxiety as Measured by the State-Trait Inventory (STAI)|Current Mood as Assessed by the Mood Form\n\nhttp://ClinicalTrials.gov/show/NCT00613405\n\n23\n\n22NCT01020019\n\nCombined Pharmacotherapy for Cannabis Dependency\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence|Marijuana Dependence\n\nDrug: Lofexidine and Dronabinol|Drug: Placebo\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 2|Phase 3180Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n#6015|P50DA009236-16|DPMC\n\nNovember 24, 2009\n\nJanuary 2010August 2014April 9, 2014April 2014\n\nNo Study Results Posted\n\nD-LUCSAugust 2014\n\nReduction in self reported days of marijuana use as measured by the Time-line Followback.|Marijuana withdrawal as measured by the MWC-10 item\n\nhttp://ClinicalTrials.gov/show/NCT01020019\n\n24\n\n23NCT01697709\n\nQuetiapine Pharmacotherapy for Cannabis Dependence\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence\n\nDrug: Quetiapine|Drug: Placebo\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 2150Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n6623|1R01DA031826\n\nSeptember 28, 2012\n\nOctober 2012July 2017October 2, 2012October 2012\n\nNo Study Results Posted\n\nQUESTJuly 2017\n\nMarijuana Use|Marijuana Abstinence|Urine toxicology|Marijuana withdrawal symptoms|Marijuana craving|Sleep disturbance\n\nhttp://ClinicalTrials.gov/show/NCT01697709\n\n25\n\n24NCT02073474\n\nAn Observational Post-Marketing Safety Registry of Sativex®\n\nEnrolling by invitation\n\nNo Results Available\n\nMultiple Sclerosis|Diabetes|Cancer|Neuropathic Pain\n\nDrug: Sativex®\n\nGW Pharmaceuticals Ltd.\n\nBoth\n\nChild|Adult|Senior\n\n3000IndustryObservational\n\nTime Perspective: Prospective\n\nGWSR10128\n\nFebruary 21, 2014\n\nFebruary 2011April 2016\n\nFebruary 25, 2014\n\nFebruary 2014\n\nNo Study Results Posted\n\nnullApril 2015\n\nIncidence rates of adverse events.|Average daily number of sprays of Sativex® used.|Number of patients experiencing fall-related injuries requiring medical attention.|Number of patients experiencing a change in driving ability.|Number of patients experiencing suicidal thoughts or attempts.|Number of patients experiencing significant psychiatric or psychotic events other than suicidality.|Incidence of patient deaths.|Number of patients receiving worthwhile benefit from Sativex®.|Number of MS patients discontinuing anti-spasticity medications.|Number of MS patients discontinuing medications for MS symptoms other than anti-spasticity medications.\n\nhttp://ClinicalTrials.gov/show/NCT02073474\n\n26\n\n25NCT01322139\n\nSativex Thorough QT/QTc Study\n\nCompleted\n\nNo Results Available\n\nEffects of Sativex on ECG\n\nDrug: Placebo spray and oral moxifloxacin placebo|Drug: Sativex spray and oral moxifloxacin placebo|Drug: Sativex spray and oral moxifloxacin placebo|Drug: Placebo spray and moxifloxacin\n\nGW Pharmaceuticals Ltd.\n\nBothAdultPhase 1258IndustryInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nGWCP0607March 23, 2011December 2007June 2008June 13, 2013June 2013\n\nNo Study Results Posted\n\nnullJune 2008\n\nTime-matched change from baseline in QTc based on an individual correction (QTcl)|QTc with Fridericia correction method (QTcF) and the QTc with Bazett correction (QTcB)|Heart Rate|PR interval|QRS interval|Uncorrected QT interval|Change in ECG morphological patterns|Correlation between the QTcl change from baseline and plasma concentrations of the parent metabolites|Adverse Events|Clinical laboratory parameters|Vital signs|Oral and physical examination|Peak plasma concentration (Cmax)|Time to peak plasma concentration (Tmax)|Area under the concentration curve (AUC(0-t) and AUC(0-inf))\n\nhttp://ClinicalTrials.gov/show/NCT01322139\n\n27\n\n26NCT01574183\n\nVilazodone Treatment for Marijuana Dependence\n\nActive, not recruiting\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Vilazodone|Drug: Placebo\n\nMedical University of South Carolina|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 276Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\n16488|R21DA034089\n\nApril 5, 2012August 2012March 2015\n\nNovember 5, 2014\n\nNovember 2014\n\nNo Study Results Posted\n\nnullAugust 2014\n\nPercent marijuana-positive urine drug screens|Time to first negative urine drug screen|Percent of marijuana-positive self-reported days|Study retention|Marijuana craving and withdrawal\n\nhttp://ClinicalTrials.gov/show/NCT01574183\n\n28\n\n27NCT00743119\n\nCharacterization of the Analgesic Effects of Oral THC and Smoked Marijuana in Non-treatment Seeking Marijuana Smokers\n\nCompleted\n\nNo Results Available\n\nPain|Mood\n\nDrug: Oral THC|Drug: Marijuana\n\nNew York State Psychiatric Institute|Research Foundation for Mental Hygiene, Inc. |National Institute on Drug Abuse (NIDA)\n\nFemaleAdultPhase 226Other|NIHInterventional\n\nEndpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)\n\n5603|5P50DA009236\n\nAugust 26, 2008June 2008December 2012February 4, 2013February 2013\n\nNo Study Results Posted\n\nnullOctober 2009\n\nanalgesic response|intoxication\n\nhttp://ClinicalTrials.gov/show/NCT00743119\n\n29\n\n28NCT01887301\n\nAssessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients\n\nCompleted\n\nNo Results Available\n\nHepatic Impairment\n\nDrug: Sativex\n\nGW Pharmaceuticals Ltd.\n\nBothAdult|SeniorPhase 132IndustryInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nGWCP10114June 24, 2013July 2013May 2014June 3, 2014June 2014\n\nNo Study Results Posted\n\nnullMay 2014\n\nPharmacokinetic analysis - Unbound maximum plasma concentration (Cmax(u)) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Unbound area under the concentration-time curve calculated to the last observable concentration at time t (AUC0-t(u)) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Unbound Area under the concentration-time curve from time zero to infinity (AUC0-inf(u)) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Maximum (peak) plasma concentration (Cmax) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Area under the concentration-time curve calculated to the last observable concentration at time t (AUC0-t) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Area under the concentration-time curve from time zero to infinity (AUC0-inf) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Half-Life (t1/2) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - time to peak concentration (Tmax) of Sativex® in healthy patients and in patients with hepatic impairment|Pharmacokinetic analysis - Apparent unbound clearance of drug from plasma (CL(u)/F) of Sativex® in healthy patients and in patients with hepatic impairment|Incidence of adverse events during the study\n\nhttp://ClinicalTrials.gov/show/NCT01887301\n\n30\n\n29NCT00373399\n\nEffects of Smoked Marijuana on Risk Taking and Decision Making Tasks\n\nRecruiting\n\nNo Results Available\n\nMarijuana Use Disorders\n\nDrug: Marijuana\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 230Other|NIHInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind\n\n5204\n\nSeptember 7, 2006\n\nMay 2006November 2006\n\nNovember 16, 2006\n\nNovember 2006\n\nNo Study Results Posted\n\nnullnull\n\nAfter smoking marijuana participants will demonstrate poorer decision-making abilities and increased risk-taking behaviors.\n\nhttp://ClinicalTrials.gov/show/NCT00373399\n\n31\n\n30NCT02240160\n\nA Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects\n\nNot yet recruiting\n\nNo Results Available\n\nTo Provide Further Information About the Potential Need for Sativex Dose Adjustments in Patient Populations.\n\nDrug: Sativex\n\nGW Pharmaceuticals Ltd.\n\nBothAdultPhase 124IndustryInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label\n\nGWCP10116|2013-004459-19\n\nSeptember 11, 2014\n\nSeptember 2014\n\nNovember 2015\n\nSeptember 11, 2014\n\nAugust 2014\n\nNo Study Results Posted\n\nnullNovember 2014\n\nPharmacokinetic parameters of THC: Cmax, AUC(0-t), and AUC(0-∞)|Pharmacokinetic parameters of CBD: Cmax, AUC(0-t), and AUC(0-∞)|Pharmacokinetic parameters of 11-hydroxy-CBD (11-OH-CBD): Cmax, AUC(0-t), and AUC(0-∞)|Pharmacokinetic parameters of 7-hydroxy-CBD (7-OH-CBD): Cmax, AUC(0-t), and AUC(0-∞)|Pharmacokinetic parameters of 6-hydroxy-CBD (6-OH-CBD): Cmax, AUC(0-t), and AUC(0-∞)|Pharmacokinetic parameters of THC: t½ and Tmax|Pharmacokinetic parameters of 11-OH-CBD: t½ and Tmax|Pharmacokinetic parameters of CBD: t½ and Tmax|Pharmacokinetic parameters of 7-OH-CBD: t½ and Tmax|Pharmacokinetic parameters of 6-OH-CBD: t½ and Tmax|Total body clearance (CL/F) of THC and CBD from plasma|The incidence of adverse events as measure of subject safety|The number of subjects with a clinically significant change in physical and oral examination results, relative to pre-treatment baseline|The number of subjects with a clinically significant change in 12-lead electrocardiogram (ECG) results, relative to pre-treatment baseline|The number of subjects with clinically significant changes in laboratory test parameters, relative to pre-treatment baseline|The number of subjects with a clinically significant change in vital signs, relative to pre-treatment baseline|The number of subjects with a clinically significant change in body temperature, relative to pre-treatment baseline|The number of subjects with a clinically significant change in body weight, relative to pre-treatment baseline\n\nhttp://ClinicalTrials.gov/show/NCT02240160\n\n32\n\n31NCT00875836\n\nBuspirone Treatment for Marijuana Dependence\n\nActive, not recruiting\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Buspirone|Drug: Placebo\n\nMedical University of South Carolina|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 4176Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nR01DA026782|DPMCDA\n\nApril 2, 2009\n\nSeptember 2009\n\nDecember 2014June 2, 2014June 2014\n\nNo Study Results Posted\n\nnullJune 2014\n\nPercent marijuana-positive urine drug screens|Time to first negative urine screen|Retention in the study|Marijuana craving and withdrawal\n\nhttp://ClinicalTrials.gov/show/NCT00875836\n\n33\n\n32NCT01598896\n\nCombination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence|Marijuana Dependence\n\nDrug: Dronabinol|Drug: Clonidine|Drug: Placebo\n\nMclean Hospital|Brain & Behavior Research Foundation\n\nBothAdultPhase 2|Phase 318OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n2010P-002262|Brain and Behavior Research\n\nMay 11, 2012May 2012June 2015\n\nOctober 10, 2014\n\nOctober 2014\n\nNo Study Results Posted\n\nDCCSJune 2015\n\nChange from baseline in cannabis use at 10 weeks|Change in withdrawal symptoms from baseline at 10 weeks|Change from baseline in cannabis use at 14 weeks|Change in withdrawal symptoms from baseline at 14 weeks\n\nhttp://ClinicalTrials.gov/show/NCT01598896\n\n34\n\n33NCT01603992\n\nQuiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms\n\nCompleted\n\nNo Results Available\n\nCannabis Abuse|Cannabis Dependence\n\nNational Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)\n\nBothAdult|Senior1230NIHObservational\n\n999906408|06-DA-N408\n\nMay 19, 2012November 2005May 2012\n\nFebruary 19, 2014\n\nMay 2012\n\nNo Study Results Posted\n\nnullnull\n\nMarijuana Quit Questionnaire|Marijuana Craving Questionnaire, and Additional Questions about Marijuana Craving\n\nhttp://ClinicalTrials.gov/show/NCT01603992\n\n35\n\n34NCT00107588\n\nMarijuana Treatment Project - 3\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nBehavioral: Reinforcement for homework completion|Behavioral: Reinforcement for Abstinence|Behavioral: Case Management\n\nUniversity of Connecticut Health Center|National Institute on Drug Abuse (NIDA)\n\nBothAdult|Senior234Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nNIDA-12728-06|R01DA012728-06|R01-12728-06\n\nApril 5, 2005February 2007August 2012January 7, 2014January 2014\n\nNo Study Results Posted\n\nMTP-3April 2011\n\nMarijuana abstinence|Self-efficacy, use of coping skills, and treatment attendance|Continuous abstinence will be predicted by (a) treatment attendance; (b) posttreatment self-efficacy for coping; and (c) use of coping skills\n\nhttp://ClinicalTrials.gov/show/NCT00107588\n\n36\n\n35NCT00656487\n\nNeurobiology of Cannabis Dependence\n\nCompleted\n\nNo Results Available\n\nCannabis Dependence|Cannabis Withdrawal\n\nDrug: rimonabant|Drug: placebo\n\nThe Scripps Research Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdult60Other|NIHInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nDA024194April 7, 2008April 2008November 2010July 19, 2012July 2012\n\nNo Study Results Posted\n\nSCCANNovember 2010\n\nCannabis Withdrawal|Neuroendocrine and monoamine assays|Neuropsychological performance|fMRI|Mood|Anxiety|Craving\n\nhttp://ClinicalTrials.gov/show/NCT00656487\n\n37\n\n36NCT01040910\n\nCannabis for Inflammatory Bowel Disease\n\nRecruiting\n\nNo Results Available\n\nCrohn's Disease|Ulcerative Colitis\n\nDrug: smoking of cannabis|Drug: smoking cigarettes with placebo\n\nMeir Medical Center\n\nBothAdult|SeniorPhase 1|Phase 220OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)\n\ncannabis1\n\nDecember 29, 2009\n\nJanuary 2010July 2012\n\nDecember 15, 2011\n\nDecember 2011\n\nNo Study Results Posted\n\nnullJune 2012\n\nreduction of CDAI by 70 points|adverse events due to cannabis smoking|change in quality of life before and at the end of study|change in IL-10. IL-2. TGF beta\n\nhttp://ClinicalTrials.gov/show/NCT01040910\n\n38\n\n37NCT01347762\n\nNabilone for Cannabis Dependence: A Pilot Study\n\nActive, not recruiting\n\nNo Results Available\n\nCannabis Dependence|Marijuana Dependence\n\nDrug: Nabilone|Drug: Placebo\n\nMclean Hospital|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 2|Phase 316Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n2010-P-000096|1K99DA029115-01\n\nApril 26, 2011June 2010April 2015\n\nOctober 10, 2014\n\nOctober 2014\n\nNo Study Results Posted\n\nNAB CANApril 2015\n\nchange from baseline in cannabis use at 10 weeks|change from baseline neuropsychological performance at 4 weeks|change from baseline cannabis use at 14 weeks|change from baseline in neuropsychological performance at 10 weeks\n\nhttp://ClinicalTrials.gov/show/NCT01347762\n\n39\n\n38NCT01762696\n\nA Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth\n\nNot yet recruiting\n\nNo Results Available\n\nMarijuana Abuse\n\nBehavioral: MET|Behavioral: Mobile self-monitoring|Behavioral: Motivational feedback messages\n\nChildren's Hospital Boston\n\nBothChild|Adult108OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)\n\n1R34DA030535-01A1\n\nJanuary 4, 2013January 2013December 2015January 4, 2013January 2013\n\nNo Study Results Posted\n\nMOMENT\n\nSeptember 2015\n\nMarijuana desire|Marijuana use following trigger exposure|Frequency of marijuana use|Percent days abstinent|Motivation to reduce marijuana use\n\nhttp://ClinicalTrials.gov/show/NCT01762696\n\n40\n\n39NCT01771731\n\nVaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease\n\nRecruiting\n\nNo Results Available\n\nSickle Cell Disease\n\nDrug: Cannabis\n\nUniversity of California, San Francisco|National Heart, Lung, and Blood Institute (NHLBI)|University of Minnesota - Clinical and Translational Science Institute\n\nBothAdult|SeniorPhase 1|Phase 235Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nU54HL117664-01|6610\n\nJanuary 14, 2013August 2014March 2016August 6, 2014August 2014\n\nNo Study Results Posted\n\nCannabis-SCDMarch 2016pain level\n\nhttp://ClinicalTrials.gov/show/NCT01771731\n\n41\n\n40NCT02283281\n\nAnesthetic Premedication With a Cannabis Extract (Cannapremed)\n\nNot yet recruiting\n\nNo Results Available\n\nPain, Postoperative|Postoperative Nausea and Vomiting|Anxiety\n\nDrug: Tetrahydrocannabinol|Drug: Acetaminophen|Drug: Midazolam|Drug: Placebo (for nabiximols)\n\nHadassah Medical Organization|GW Pharmaceuticals Ltd.\n\nBothAdultPhase 2|Phase 3200Other|IndustryInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nCannapremed-HMO-CTIL\n\nNovember 2, 2014\n\nDecember 2014February 2016\n\nNovember 4, 2014\n\nNovember 2014\n\nNo Study Results Posted\n\nCannapremedDecember 2015\n\nPostoperative pain - VAS|Postoperative pain - PCA|Postoperative nausea and vomiting (PONV) score|Anxiety - VAS|Cannabinoid blood levels\n\nhttp://ClinicalTrials.gov/show/NCT02283281\n\n42\n\n41NCT02165176\n\nPharmacokinetic and Pharmacodynamic Effects of Oral Cannabis\n\nRecruiting\n\nNo Results Available\n\nCannabis\n\nDrug: Oral cannabis\n\nJohns Hopkins University|Substance Abuse and Mental Health Services Administration (SAMHSA)|RTI International\n\nBothAdultPhase 124Other|U.S. FedInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Outcomes Assessor)\n\nIRB00035394June 12, 2014June 2014\n\nSeptember 2014\n\nJune 13, 2014June 2014\n\nNo Study Results Posted\n\nnull\n\nSeptember 2014\n\nBlood THC|Urine THC-COOH|Oral Fluid THC|Subjective rating of \\\"Drug Effect\\\",\"http://ClinicalTrials.gov/show/NCT02165176\n\n43\n\n42NCT01592409\n\nCannabis Effects on Driving-related Skills of Young Drivers\n\nRecruiting\n\nNo Results Available\n\nPsychomotor Impairment\n\nDrug: delta-9-tetrahydrocannabinol|Drug: Placebo\n\nCentre for Addiction and Mental Health|Canadian Institutes of Health Research (CIHR)|Health Canada\n\nBothAdult142OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)\n\n125/2011May 3, 2012July 2012July 2015July 16, 2014July 2014\n\nNo Study Results Posted\n\nnullMay 2015\n\nPsychomotor impairment (driving)|Area under the blood concentration versus time curves for delta-9-tetrahydrocannabinol, carboxy-tetrahydrocannabinol, and 11-hydroxy-tetrahydrocannabinol|Vital signs|Subjective drug effects|Cognitive testing|Urine carboxy-tetrahydrocannabinol to creatinine ratio\n\nhttp://ClinicalTrials.gov/show/NCT01592409\n\n44\n\n43NCT00149643\n\nEffectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence\n\nCompletedHas Results\n\nDepressive Disorder, Major|Cannabis Abuse\n\nDrug: Fluoxetine|Other: Placebo\n\nUniversity of Pittsburgh|National Institute on Drug Abuse (NIDA)\n\nBothChild|AdultPhase 270Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nNIDA-19142-1|R01DA019142|DPMC\n\nSeptember 6, 2005\n\nSeptember 2004\n\nDecember 2012June 17, 2013June 2013February 8, 2012CADYAugust 2009\n\nDays Per Week of Cannabis Use.|Depression Symptoms at Week 12|Number of Cannabis Use Disorder Criterion Met at a Particular Time Point.\n\nhttp://ClinicalTrials.gov/show/NCT00149643\n\n45\n\n44NCT00743145\n\nEffects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana\n\nCompleted\n\nNo Results Available\n\nMarijuana Smoking\n\nDrug: Naltrexone|Drug: Smoked marijuana\n\nNew York State Psychiatric Institute|Research Foundation for Mental Hygiene, Inc. |National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 248Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind\n\n5693August 26, 2008May 2008\n\nSeptember 2009\n\nSeptember 22, 2009\n\nSeptember 2009\n\nNo Study Results Posted\n\nnullJuly 2009\n\nhttp://ClinicalTrials.gov/show/NCT00743145\n\n46\n\n45NCT01179425\n\nSex Differences in Attentional Bias in Marijuana-dependent Individuals\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nOther: Cognitive stressor\n\nMedical University of South Carolina\n\nBothAdult40OtherInterventional\n\nAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label\n\nHR# 19292\n\nNovember 17, 2009\n\nAugust 2009February 2011April 13, 2011April 2011\n\nNo Study Results Posted\n\nnullFebruary 2011\n\nPrimary outcome measures will be obtained from the auditory odd-ball task: differences while viewing the marijuana vs neutral video in reaction time (msec), errors of omission (%), and errors of commission (%).|Secondary measures include subjective (craving and stress), physiological (heart rate and skin conductance), and stress hormone level (cortisol) assessments.\n\nhttp://ClinicalTrials.gov/show/NCT01179425\n\n47\n\n46NCT00158249\n\nEffects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals\n\nCompletedHas ResultsMarijuana Abuse\n\nDrug: citicoline|Drug: placebo\n\nMclean Hospital|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 221Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nNIDA-19238-1|R01DA019238|DPMC|R01DA024007\n\nSeptember 8, 2005\n\nSeptember 2009\n\nOctober 2014\n\nOctober 15, 2014\n\nOctober 2014\n\nOctober 15, 2014\n\nnullJanuary 2013\n\nMarijuana Use|Neurocognitive Function\n\nhttp://ClinicalTrials.gov/show/NCT00158249\n\n48\n\n47NCT01322464\n\nStudy to Assess Food Effect on Sativex Bioavailability\n\nCompleted\n\nNo Results Available\n\nFood Effect\n\nDrug: Sativex|Drug: Sativex|Drug: Sativex|Drug: Sativex\n\nGW Pharmaceuticals Ltd.\n\nMaleAdultPhase 125IndustryInterventional\n\nAllocation: Randomized|Endpoint Classification: Bio-availability Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Open Label\n\nGWCP0601March 23, 2011January 2008February 2008June 13, 2013June 2013\n\nNo Study Results Posted\n\nnullFebruary 2008\n\nPrimary PK Endpoints|Secondary PK measures|Safety and tolerability of Sativex\n\nhttp://ClinicalTrials.gov/show/NCT01322464\n\n49\n\n48NCT01204723\n\nMedications Development for the Treatment of Cannabis Related Disorders\n\nCompleted\n\nNo Results Available\n\nNicotine Withdrawal|Marijuana Dependence|Cannabis Dependence|Nicotine Dependence|Cannabis Abuse\n\nDrug: Placebo Aprepitant|Drug: Active Aprepitant\n\nUniversity of Virginia|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 163Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n14392|R01DA027131\n\nSeptember 14, 2010\n\nAugust 2009April 2012May 31, 2012May 2012\n\nNo Study Results Posted\n\nMTCJanuary 2012\n\nwithdrawal symptom severity, measured on a 0 (not at all) to 3 (severe) scale|\\\"craving\\\" measured using the Marijuana craving questionaire and the tobacco craving questionaire|reinforcing effects, as measured using the Multiple Choice Questionaire|sleep quality|Neurocognitive Function|Number of Participants with Adverse Events as a Measure of Safety and Tolerability\n\nhttp://ClinicalTrials.gov/show/NCT01204723\n\n50\n\n49NCT02249299\n\nExperimental Medicine in ADHD - Cannabinoids\n\nRecruiting\n\nNo Results Available\n\nAttention Deficit Hyperactivity Disorder (ADHD)\n\nDrug: Sativex Oromucosal Spray|Drug: Placebo\n\nKing's College London|South London and Maudsley NHS Foundation Trust\n\nBothAdult30OtherInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nEMA-C\n\nSeptember 3, 2014\n\nAugust 2014December 2015\n\nSeptember 23, 2014\n\nSeptember 2014\n\nNo Study Results Posted\n\nEMA-CAugust 2015\n\nChange in performance on the QB Test using the average of 3 weighted indexes: 'activity' 'inattention' and 'impulsivity'|ADHD symptoms of inattention, hyperactivity-impulsivity and emotional lability|Self-report behavioural questionnaire|Self-report behavioural questionnaires|Change in cognitive performance\n\nhttp://ClinicalTrials.gov/show/NCT02249299\n\n51\n\n50NCT01335789\n\nEffect of Oxytocin on Stress in Marijuana Users\n\nCompletedHas Results\n\nMarijuana Dependence\n\nDrug: Oxytocin|Drug: Saline\n\nMedical University of South Carolina\n\nBothAdult16OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)\n\n20274April 8, 2011March 2011July 2012July 29, 2014July 2014June 2, 2014nullJuly 2012\n\nStress (as Measured by Cortisol)|Stress (as Measured by Subjective Report)|Craving (as Measured by the Marijuana Craving Questionnaire)\n\nhttp://ClinicalTrials.gov/show/NCT01335789\n\n52\n\n51NCT02191605\n\nComputer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy\n\nNot yet recruiting\n\nNo Results Available\n\nMarijuana Use|Pregnancy\n\nBehavioral: eSBIRT|Behavioral: Tailored texting\n\nWayne State University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)\n\nFemaleAdultPhase 180Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Outcomes Assessor)\n\nR34DA036788|1R34DA036788\n\nJuly 14, 2014April 2015March 2017July 14, 2014July 2014\n\nNo Study Results Posted\n\nnullOctober 2016\n\nMarijuana Use - 7 day|Marijuana Use - 90 day\n\nhttp://ClinicalTrials.gov/show/NCT02191605\n\n53\n\n52NCT00594659\n\nDevelopment and Efficacy Test of Computerized Treatment for Marijuana Dependence\n\nCompletedHas Results\n\nMarijuana Abuse and Dependence\n\nBehavioral: Psychotherapy|Behavioral: Computerized Psychotherapy|Behavioral: Motivational enhancement therapy\n\nDartmouth-Hitchcock Medical Center\n\nBothAdult75OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n88268|1R01DA023526-01|1R01DA023526-02|1R01DA023526-03\n\nJanuary 7, 2008November 2008July 2012\n\nDecember 3, 2013\n\nDecember 2013April 16, 2013nullJuly 2012\n\nConsecutive Weeks of Marijuana Abstinence|Point Prevalence Abstinence Post Treatment\n\nhttp://ClinicalTrials.gov/show/NCT00594659\n\n54\n\n53NCT00838448\n\nInteractions Between Physical Activity and Cannabis Use in Adults\n\nCompleted\n\nNo Results Available\n\nCannabis Dependence\n\nBehavioral: Exercise\n\nVanderbilt University\n\nBothAdult30OtherInterventional\n\nAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Open Label\n\n81302January 23, 2009January 2009June 2013June 11, 2013June 2013\n\nNo Study Results Posted\n\nnullJanuary 2011\n\nCraving for cannabis\n\nhttp://ClinicalTrials.gov/show/NCT00838448\n\n55\n\n54NCT01555983\n\nVaporized Cannabis and Spinal Cord Injury Pain\n\nCompleted\n\nNo Results Available\n\nSpinal Cord Injuries\n\nDrug: Cannabis|Drug: Cannabis|Drug: Placebo\n\nBarth Wilsey|VA Northern California Health Care System|University of California, San Diego|National Institute on Drug Abuse (NIDA)|University of California, Davis\n\nBothAdult|SeniorPhase 2|Phase 342\n\nOther|U.S. Fed|NIH\n\nInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\n256412-3|1R01DA030424-01A1\n\nFebruary 9, 2012July 2012August 2014\n\nSeptember 4, 2014\n\nSeptember 2014\n\nNo Study Results Posted\n\nnullAugust 2014\n\nAnalgesia|Neuropsychological Testing of Memory|Psychomotor Performance|Attention\n\nhttp://ClinicalTrials.gov/show/NCT01555983\n\n56\n\n55NCT00682929\n\nCannabis for Spasticity in Multiple Sclerosis\n\nRecruiting\n\nNo Results Available\n\nMultiple Sclerosis\n\nDrug: Smoked Cannabis|Drug: Smoked Cannabis and oral marinol|Drug: Placebo\n\nUniversity of California, Davis|National Multiple Sclerosis Society\n\nBothAdult|SeniorPhase 1|Phase 260OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)\n\n200311404|MS Society Award # RG 3781-A-1\n\nMay 19, 2008March 2003June 2013July 5, 2012July 2012\n\nNo Study Results Posted\n\nnullJanuary 2013\n\nChange in an objective measurement of spasticity between the pretreatment assessment and the 3- and 7-week assessments|Differences between active agent and placebo in the changes in Ashworth Scale, Functional System Score, Expanded Disability Status Score, Ambulation Index, Functional Composite Score, and Quality of Life Inventory.\n\nhttp://ClinicalTrials.gov/show/NCT00682929\n\n57\n\n56NCT02210195\n\nPharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence|Alcohol Dependence|Cannabis Use Disorder|Alcohol Use Disorder\n\nDrug: aprepitant|Drug: Placebo|Behavioral: Standardized behavioral therapy\n\nThe Scripps Research Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdult|SeniorPhase 240Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nR01DA030988-04S1\n\nJuly 31, 2014July 2014January 2017August 4, 2014August 2014\n\nNo Study Results Posted\n\nnullJanuary 2017\n\nMarijuana|Drinking\n\nhttp://ClinicalTrials.gov/show/NCT02210195\n\n58\n\n57NCT00374127\n\nComparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Marijuana\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 236Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Single Blind\n\n4683\n\nSeptember 7, 2006\n\nDecember 2004August 2008July 26, 2010August 2008\n\nNo Study Results Posted\n\nnullAugust 2008\n\nhttp://ClinicalTrials.gov/show/NCT00374127\n\n59\n\n58NCT02088177\n\nStudy of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence\n\nNot yet recruiting\n\nNo Results Available\n\nCannabis Dependence\n\nDrug: Long-acting injectable naltrexone\n\nNew York State Psychiatric Institute\n\nBothAdultPhase 1|Phase 27OtherInterventional\n\nEndpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n#6799|DA009236\n\nFebruary 25, 2014\n\nMarch 2014March 2015March 12, 2014October 2013\n\nNo Study Results Posted\n\nnullDecember 2014\n\nReduction in marijuana use|Proportion of participants receiving the second injection of study medication|Number and severity of adverse events associated with naltrexone and its injection|Reduction in marijuana use as measured by urine toxicology\n\nhttp://ClinicalTrials.gov/show/NCT02088177\n\n60\n\n59NCT00893269\n\nThe Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: eszopiclone|Drug: Placebo|Drug: ramelteon|Drug: zolpidem\n\nJohns Hopkins University|Food and Drug Administration (FDA)|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 136\n\nOther|U.S. Fed|NIH\n\nInterventional\n\nAllocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Outcomes Assessor)\n\nNA_00017909|R21-DA025794\n\nApril 30, 2009October 2008October 2010\n\nDecember 3, 2013\n\nDecember 2013\n\nNo Study Results Posted\n\nnullOctober 2010\n\nMarijuana Withdrawal|Objective Sleep Assessment|Cognitive Performance\n\nhttp://ClinicalTrials.gov/show/NCT00893269\n\n61\n\n60NCT00395044\n\nGabapentin Treatment of Cannabis Dependence\n\nCompleted\n\nNo Results Available\n\nCannabis Dependence\n\nDrug: gabapentin|Behavioral: Standardized behavioral therapy\n\nNational Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 1|Phase 250NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind\n\nDA020766-01|5 R21 DA020766-01\n\nNovember 1, 2006\n\nAugust 2006July 2008February 6, 2009February 2009\n\nNo Study Results Posted\n\nnullJuly 2008\n\nCannabis use|Cannabis withdrawal|Sleep|Mood|Craving|Cannabis use consequences\n\nhttp://ClinicalTrials.gov/show/NCT00395044\n\n62\n\n61NCT01776970\n\nSafety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease\n\nRecruiting\n\nNo Results Available\n\nMotor Neuron Disease|Amyotrophic Lateral Sclerosis (ALS)\n\nDrug: Cannabis Sativa extract Oromucosal spray\n\nOspedale San Raffaele|Fondazione Salvatore Maugeri|Niguarda Hospital|University of Padova\n\nBothAdult|SeniorPhase 2|Phase 360OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nCANALSJanuary 24, 2013January 2013December 2014January 24, 2013January 2013\n\nNo Study Results Posted\n\nCANALS\n\nSeptember 2014\n\nmodified 5 - points modified Ashworth scale (AS).|Mean weekly spasticity, spasm frequency and sleep disruption Numeric Rating Scale (NRS) score\n\nhttp://ClinicalTrials.gov/show/NCT01776970\n\n63\n\n62NCT01400243\n\nNicotine for Marijuana Withdrawal\n\nRecruiting\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Nicotine|Drug: Placebo Patch\n\nSouthern Illinois University Carbondale|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 4116Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Factorial Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Investigator)\n\nNIH/NIDA 1R01DA031006 - 01|R01DA031006\n\nMarch 21, 2011April 2011July 2014February 3, 2014February 2014\n\nNo Study Results Posted\n\nNMWJune 2014\n\nMarijuana withdrawal symptoms (mood, use, and urge to use marijuana)|Patch Guess and Attributions Questionnaire|Blood Pressure|Tobacco dependence.|Tobacco and nicotine intake|Body Weight|THC Intake|Heart Rate\n\nhttp://ClinicalTrials.gov/show/NCT01400243\n\n64\n\n63NCT00308555\n\nOpioid and Cannabinoid Pharmacokinetic Interactions\n\nCompletedHas ResultsPain|NeoplasmsDrug: Cannabis\n\nUniversity of California, San Francisco|National Institute on Drug Abuse (NIDA)\n\nBothAdult|SeniorPhase 124Other|NIHInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nCC # 064|1 R21 DA 020831-01\n\nMarch 27, 2006May 2006March 2009May 28, 2013May 2013May 23, 2013nullMarch 2009\n\nDisposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use\n\nhttp://ClinicalTrials.gov/show/NCT00308555\n\n65\n\n64NCT02030665\n\nMarijuana Treatment Project 4\n\nRecruiting\n\nNo Results Available\n\nMarijuana Dependence\n\nBehavioral: Contingency Management|Behavioral: Individualized Assessment & Treatment|Behavioral: Cognitive-Behavioral Treatment\n\nUniversity of Connecticut Health Center\n\nBothAdult|Senior275OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nNIDA-12728-11January 7, 2014February 2013December 2017January 7, 2014January 2014\n\nNo Study Results Posted\n\nMTP4March 2016\n\nMarijuana Use|Coping Skills\n\nhttp://ClinicalTrials.gov/show/NCT02030665\n\n66\n\n65NCT00480441\n\nEffectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Dronabinol|Behavioral: BRENDA therapy|Drug: Placebo\n\nUniversity of Pennsylvania|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 261Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)\n\n5-P60-DA-005186-19|5P60DA005186-19\n\nMay 30, 2007August 2006July 2009January 17, 2012January 2012\n\nNo Study Results Posted\n\nnullJune 2009\n\nCannabis dependent patients will be able to tolerate dronabinol.|Dronabinol will attenuate cannabis withdrawal.|The quantitative THC and self-report measurements will decrease over the time of study.|Cannabis dependent patients will complete neurocognitive assessments with dronabinol improving performance in certain spheres of function.|Cannabis dependent patients will demonstrate physiological changes in response to cue-induced craving which will be attenuated by dronabinol treatment.|Select group of cannabis dependent patients will complete fMRI scans with demonstrable dronabinol related changes in brain activation.|Structural and perfusion brain differences will be correlated with performance on neurocognitive tasks\n\nhttp://ClinicalTrials.gov/show/NCT00480441\n\n67\n\n66NCT00270803\n\nThe Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana\n\nCompleted\n\nNo Results Available\n\nMarijuana Dependence\n\nDrug: Tetra Hydro Cannabinol (THC)\n\nTel-Aviv Sourasky Medical Center|Hadassah Medical Organization\n\nBothAdult12OtherInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nTASMC-05-EE-03-124-CTIL\n\nDecember 25, 2005\n\nJuly 2004December 2005May 6, 2008December 2005\n\nNo Study Results Posted\n\nnullDecember 2005\n\nBrain metabolic activity (FDG)|Reaction time (RTs) and errors in performance|Subjective ratings on visual analog scale\n\nhttp://ClinicalTrials.gov/show/NCT00270803\n\n68\n\n67NCT01639872\n\nClozapine for Cannabis Use in Schizophrenia\n\nRecruiting\n\nNo Results Available\n\nSchizophrenia|Cannabis Abuse|Cannabis Dependence|Dual Diagnosis\n\nDrug: Clozapine|Drug: Risperidone\n\nDartmouth-Hitchcock Medical Center|University of South Carolina|Michigan State University|University of Miami|University of Massachusetts, Worcester\n\nBothAdultPhase 4132OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\n1R01DA032533-01A1\n\nJuly 11, 2012April 2013October 2017August 6, 2014August 2014\n\nNo Study Results Posted\n\nCLOCSOctober 2016\n\nIntensity of cannabis use|Frequency of cannabis use|Symptoms of Schizophrenia|Quality of Life|Neuropsychological functioning|Reward responsiveness\n\nhttp://ClinicalTrials.gov/show/NCT01639872\n\n69\n\n68NCT00249509\n\nEffectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals\n\nCompleted\n\nNo Results Available\n\nMarijuana Abuse\n\nDrug: Nefazodone|Drug: Bupropion\n\nNational Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 2132NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind\n\nNIDA-13191-1|R01-DA013191-1|DPMC\n\nNovember 3, 2005\n\nSeptember 2000\n\nSeptember 2004\n\nOctober 15, 2009\n\nOctober 2009\n\nNo Study Results Posted\n\nnull\n\nSeptember 2004\n\nMarijuana use|Marijuana withdrawal\n\nhttp://ClinicalTrials.gov/show/NCT00249509\n\n70\n\n69NCT01292642\n\nCognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence\n\nCompletedHas Results\n\nCannabis Dependence|Nicotine Dependence\n\nBehavioral: Cognitive Behavioral Therapy|Drug: Nicotine Replacement Therapy\n\nMclean Hospital|Harvard Medical School\n\nBothAdultPhase 212OtherInterventional\n\nEndpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n2008-P-000927February 8, 2011August 2009June 2011August 13, 2013August 2013June 25, 2013CBT-MJ-NICJune 2011\n\nCigarette Use|Cannabis Use|Client Satisfaction Questionnaire (CSQ-8) at 10 Weeks\n\nhttp://ClinicalTrials.gov/show/NCT01292642\n\n71\n\n70NCT01812603\n\nA Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma\n\nActive, not recruiting\n\nNo Results Available\n\nCancerDrug: Sativex\n\nGW Research Ltd\n\nBothAdult|SeniorPhase 1|Phase 26IndustryInterventional\n\nEndpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nGWCA1208 Part A\n\nMarch 14, 2013September 2013October 2015\n\nSeptember 2, 2014\n\nSeptember 2014\n\nNo Study Results Posted\n\nnullOctober 2015\n\nThe incidence of adverse events in patients receiving Sativex in combination with dose-intense Temozolomide in the open-label phase of the study|The number of patients with Progression Free Survival at six months (PFS6)|Overall Survival\n\nhttp://ClinicalTrials.gov/show/NCT01812603\n\n75\n\n74NCT01031290\n\nPilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving\n\nWithdrawn\n\nNo Results Available\n\nCannabis Use\n\nDevice: Repetitive Transcranial Magnetic Stimulation\n\nNational Institute on Drug Abuse (NIDA)|University of Maryland|National Institutes of Health Clinical Center (CC)\n\nBothAdultPhase 10NIH|OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind\n\n999909443|09-DA-N443\n\nDecember 11, 2009\n\nAugust 2009February 2012March 20, 2012February 2012\n\nNo Study Results Posted\n\nnullJanuary 2012\n\nCannabis craving by Marijuana Craving Questionnaire and visual-analogue scales.|Cannabis use by urine drug testing and self-report; Safety and tolerability, using side-effects checklist.\n\nhttp://ClinicalTrials.gov/show/NCT01031290\n\n76\n\n75NCT01473719\n\nEmerging Adults Who Use Alcohol and Marijuana\n\nRecruiting\n\nNo Results Available\n\nAlcohol Use|Marijuana Use|Sexually Transmitted Infections\n\nBehavioral: motivational intervention|Behavioral: health education\n\nButler HospitalBothAdultPhase 4500OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)\n\nR01 AA020509\n\nNovember 15, 2011\n\nJanuary 2012nullJuly 16, 2014July 2014\n\nNo Study Results Posted\n\nHEAT\n\nSeptember 2015\n\nalcohol use|marijuana use|sexually transmitted infection\n\nhttp://ClinicalTrials.gov/show/NCT01473719\n\n77\n\n76NCT00798109\n\nEffect of Motivational Therapy on Schizophrenia With Cannabis Misuse\n\nCompleted\n\nNo Results Available\n\nSchizophrenia|Cannabis Dependence, Continuous\n\nBehavioral: Motivational therapy|Behavioral: Usual care\n\nAssistance Publique - Hôpitaux de Paris\n\nBothAdult|Senior97OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nP 070156|AOM 07007\n\nSeptember 30, 2008\n\nNovember 2008April 2013June 13, 2014June 2014\n\nNo Study Results Posted\n\nSCHIZOCANOctober 2012\n\nCannabis consumption evaluated by the Time-Line Follow Back at 6 months with mean percentage of abstinent day|PANSS, GAF, number of DSM-IV criteria of cannabis dependence, May scale for treatment response, SF-12, la URICA, number of hospitalisation, mean number of joints per week, D9THC urinanalysis at 6M and cannabis consumption evaluated by the TLFB at 6M\n\nhttp://ClinicalTrials.gov/show/NCT00798109\n\n78\n\n77NCT00217971\n\nDronabinol Treatment for Marijuana Addiction\n\nCompletedHas ResultsMarijuana Abuse\n\nDrug: Dronabinol|Drug: Placebo\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 2156Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\n#4886-NIDA-09236-11|P50DA009236|P50DA009236-11|DPMC\n\nSeptember 16, 2005\n\nMarch 2005December 2009June 28, 2012June 2012\n\nSeptember 13, 2011\n\nMARINOLDecember 2009\n\nProportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial\n\nhttp://ClinicalTrials.gov/show/NCT00217971\n\n79\n\n78NCT01025700\n\nNabilone & Marijuana Addiction\n\nCompleted\n\nNo Results Available\n\nMarijuana Smoking\n\nDrug: Cesemat\n\nUniversity of British Columbia\n\nBothAdultPhase 2|Phase 335OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)\n\nH08-01999\n\nDecember 2, 2009\n\nJune 2009October 2010\n\nFebruary 16, 2011\n\nFebruary 2011\n\nNo Study Results Posted\n\nnullJune 2010\n\nSafety and tolerability to Nabilone|Marijuana craving questionnaire\n\nhttp://ClinicalTrials.gov/show/NCT01025700\n\n80\n\n79NCT00783185\n\nDual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment\n\nCompleted\n\nNo Results Available\n\nPsychotic Disorders|Marijuana Abuse|Intervention\n\nBehavioral: Cannabis-Consumption-Reduction-Training|Behavioral: Social competence Training\n\nUniversity of Konstanz\n\nBothAdultPhase 150OtherInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\nCRET\n\nOctober 30, 2008\n\nJanuary 2006January 2010\n\nJanuary 11, 2010\n\nOctober 2008\n\nNo Study Results Posted\n\nnullJune 2009\n\nPANSS Positive and Negative Symptom Scale|Urinstatus for cannabinoids\n\nhttp://ClinicalTrials.gov/show/NCT00783185\n\n81\n\n80NCT00530764\n\nA Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.\n\nCompletedHas Results\n\nPalliative Care|Pain|Cancer\n\nDrug: Sativex Low Dose|Drug: Sativex Medium Dose|Drug: Sativex High Dose\n\nGW Pharmaceuticals Ltd.|Quintiles\n\nBothAdult|SeniorPhase 2360IndustryInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nGWCA0701\n\nSeptember 13, 2007\n\nNovember 2007January 2010June 13, 2013June 2013March 2, 2011SPRAYJanuary 2010\n\nNumber of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline|Change in Cumulative Average Pain Response Curves|Change in Mean Daily NRS Pain Score (Average Pain).|Change in Mean Daily NRS Pain Score (Worst Pain).|Change in Sleep Disruption NRS|Change in Brief Pain Inventory - Short Form (BPI-SF)|Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)|Change in Patient Global Impression of Change - PGIC|Change in Montgomery Asberg Depression Rating Scale (MADRS)\n\nhttp://ClinicalTrials.gov/show/NCT00530764\n\n82\n\n81NCT01617616\n\nTilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects\n\nActive, not recruiting\n\nNo Results Available\n\nPostural Orthostatic Tachycardia Syndrome|Syncope, Vasovagal|Neurocardiogenic Syncope\n\nWake Forest Baptist Health|American Heart Association\n\nBothChild|Adult48OtherObservational\n\nObservational Model: Cohort|Time Perspective: Prospective\n\nWFUBAHA01April 10, 2012March 2012March 2014March 27, 2013March 2013\n\nNo Study Results Posted\n\nPOTSDecember 2013\n\nAutonomic Testing in Suspected POTS Subjects|Change in Heart Rate and Blood Pressure in Suspected POTS Subjects\n\nhttp://ClinicalTrials.gov/show/NCT01617616\n\n83\n\n82NCT01037608\n\nEffects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation\n\nCompleted\n\nNo Results Available\n\nCannabis|Dependence|Cannabis Abuse|Pharmacokinetics|fMRI\n\nDrug: Sativex(Registered Trademark)|Drug: THC\n\nNational Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)\n\nBothAdultPhase 1108NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Double-Blind\n\n999907423|07-DA-N423\n\nDecember 19, 2009\n\nMay 2007December 2011\n\nDecember 31, 2011\n\nDecember 2011\n\nNo Study Results Posted\n\nnullAugust 2011\n\nPharmacokinetics/Pharmacodynamics\n\nhttp://ClinicalTrials.gov/show/NCT01037608\n\n84\n\n83NCT00542750\n\nAn Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents\n\nCompleted\n\nNo Results Available\n\nCannabis Dependence\n\nDrug: N-Acetylcysteine\n\nMedical University of South Carolina|National Institute on Drug Abuse (NIDA)|American Academy of Child Adolescent Psychiatry.\n\nBothChild|AdultPhase 1|Phase 224Other|NIHInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n5K12 DA 000357 NAC MJ Pilot\n\nOctober 10, 2007\n\nJanuary 2008December 2008\n\nFebruary 12, 2009\n\nFebruary 2009\n\nNo Study Results Posted\n\nNAC MJ PilotDecember 2008\n\nfeasibility of recruitment, measured by number of participants recruited and retained during study period|tolerability of study medication, measured by adverse events documentation and a checklist of adverse events (MOSES scale)|marijuana use rate during participation as compared to use rate prior to participation, as recorded in marijuana diary and Timeline Follow-Back|difference in reactivity to marijuana cues between pre-medication and medication conditions, measured by Marijuana Craving Questionnaire and physiologic data (skin conductance and heart rate)\n\nhttp://ClinicalTrials.gov/show/NCT00542750\n\n85\n\n84NCT00252980\n\nCANDIS - Targeted Treatment for Cannabis Disorders\n\nActive, not recruiting\n\nNo Results Available\n\nCannabis Use Disorder\n\nBehavioral: Psychotherapy\n\nTechnische Universität Dresden\n\nBoth\n\nChild|Adult|Senior\n\nPhase 2210OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n01EB0440\n\nNovember 14, 2005\n\nJanuary 2006March 2007January 15, 2007January 2007\n\nNo Study Results Posted\n\nnullnull\n\n- total quit rates, defined as no evidence of cannabis use during the past 4 weeks as evidenced by self report and a negative urine screen; number of times a cannabis product was used in the past 4 weeks|; decrease in ASI total score; retention rate|- number of slips; relapse; abstinence from all legal drugs; number of times of drug use other than cannabis\n\nhttp://ClinicalTrials.gov/show/NCT00252980\n\n86\n\n85NCT01039415\n\nAttempts to Stop/Reduce Marijuana Among Dependent Users\n\nCompleted\n\nNo Results Available\n\nMarijuana Abuse|Marijuana Dependence\n\nUniversity of Vermont|National Institute on Drug Abuse (NIDA)\n\nBothAdult|Senior234Other|NIHObservational\n\nObservational Model: Case-Only|Time Perspective: Prospective\n\nCHRBS #09-005|R01DA024691\n\nDecember 24, 2009\n\nJune 2010October 2012\n\nSeptember 17, 2013\n\nSeptember 2013\n\nNo Study Results Posted\n\nnullOctober 2012\n\ninitiation of a quit or reduction attempt|duration of a quit attempt\n\nhttp://ClinicalTrials.gov/show/NCT01039415\n\n87\n\n86NCT00498550\n\nTreatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual\n\nCompletedHas Results\n\nSchizophrenia|Dual Diagnosis|Schizoaffective Disorder|Psychotic Disorder|Cannabis Abuse\n\nDrug: Clozapine|Drug: Treatment as usual\n\nDartmouth-Hitchcock Medical Center|National Institute on Drug Abuse (NIDA)|University of Missouri, Kansas City|VA Medical Center-West Los Angeles|University of South Carolina\n\nBothAdultPhase 431\n\nOther|NIH|U.S. Fed\n\nInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)\n\nR01DA013196|R01 DA013196|DPMCDA\n\nJuly 6, 2007October 2000March 2009\n\nDecember 15, 2011\n\nDecember 2011\n\nSeptember 28, 2011\n\nnullMarch 2009\n\nDays of Cannabis Use as Measured by the Timeline Followback|Brief Psychiatric Rating Scale (BPRS) Total Score\n\nhttp://ClinicalTrials.gov/show/NCT00498550\n\n88\n\n87NCT00974376\n\nGabapentin Treatment of Cannabis Dependence\n\nRecruiting\n\nNo Results Available\n\nCannabis Dependence|Cannabis Withdrawal|Cognitive Deficits\n\nDrug: gabapentin 1200mg/day|Drug: Placebo\n\nThe Scripps Research Institute\n\nBothAdultPhase 2150OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nDA026758\n\nSeptember 1, 2009\n\nAugust 2009May 2015July 23, 2014July 2014\n\nNo Study Results Posted\n\nnullMay 2015Cannabis Use\n\nhttp://ClinicalTrials.gov/show/NCT00974376\n\n89\n\n88NCT00943930\n\nMarijuana Drug Discrimination and Self-Administration\n\nActive, not recruiting\n\nNo Results Available\n\nMarijuana Abuse\n\nDrug: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC\n\nWayne State University|National Institute on Drug Abuse (NIDA)\n\nBothAdult25Other|NIHObservational\n\nObservational Model: Case-Only|Time Perspective: Prospective\n\nNIDA DA026761|R01DA026761-01\n\nJuly 21, 2009April 2009December 2014March 20, 2014March 2014\n\nNo Study Results Posted\n\nDDCDecember 2012\n\nhttp://ClinicalTrials.gov/show/NCT00943930\n\n90\n\n89NCT00131456\n\nFree Venlafaxine Treatment for Marijuana Addiction and Depression - 1\n\nCompletedHas Results\n\nDepression|Marijuana Abuse\n\nDrug: Venlafaxine|Drug: Placebo\n\nNew York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)\n\nBothAdultPhase 2123Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\n#4695|R01DA015451\n\nAugust 16, 2005March 2004December 2010June 4, 2013June 2013April 18, 2013VENDecember 2010\n\nTwo Consecutive Weeks of Marijuana Abstinence\n\nhttp://ClinicalTrials.gov/show/NCT00131456\n\n91\n\n90NCT00687609\n\nPilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE\n\nTerminatedHas Results\n\nAttention Deficit Hyperactivity Disorder|Cannabis Abuse\n\nDrug: Atomoxetine\n\nEli Lilly and Company\n\nBothChildPhase 47IndustryInterventional\n\nEndpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label\n\n12382|B4Z-UT-LYEL\n\nMay 28, 2008\n\nSeptember 2008\n\nJune 2009August 18, 2010August 2010July 22, 2010PEACEJune 2009\n\nAttention Deficit Hyperactivity Disorder (ADHD) Rating Scale-IV-Parent Version: Investigator Scored Total Score at 12 Weeks|Clinical Global Impression-ADHD-Improvement (CGI-ADHD-I) at 12 Weeks|Change From Baseline to 12 Weeks in Global Impression of Perceived Difficulties (GIPD) - Participant Rated Version|Change From Baseline to 12 Weeks in the Children's Depression Rating Scale-Revised (CDRS-R)|Change From Baseline to 12 Weeks in the Pediatric Anxiety Rating Scale (PARS)|Change From Baseline to 12 Weeks in the Marijuana Craving Questionnaire (MCQ)|Change From Baseline in Neurocognitive Functioning as Measured at 12 Weeks by a Test Battery: Stop-Signal Task|Change From Baseline in Neurocognitive Functioning as Measured at 12 Weeks by a Test Battery: Contingency Task|Change From Baseline in Neurocognitive Functioning as Measured at 12 Weeks by a Test Battery: Time Reproduction Task|C-SSRS Suicidal Ideation By Visit at Week 4: Non-Specific Active Suicidal Thoughts|C-SSRS Intensity of Ideation (Most Common Ideation Type and Most Severe Ideation Type) By Visit at Week 4\n\nhttp://ClinicalTrials.gov/show/NCT00687609\n\n92\n\n91NCT02061020\n\nStudy of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users\n\nRecruiting\n\nNo Results Available\n\nOccasional (1-2 Joints Per Week) and Chronic (1-2 Joints Per Day) Cannabis Users\n\nDrug: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo\n\nAssistance Publique - Hôpitaux de Paris\n\nMaleAdult30OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)\n\nAOR12144 / P111114|2013-A00245-40\n\nDecember 18, 2013\n\nJanuary 2014December 2015\n\nFebruary 11, 2014\n\nMay 2013\n\nNo Study Results Posted\n\nVIGICANNNovember 2015\n\nAbility to drive a motor vehicle measured using a driving simulator|Psychomotor Vigilance Test (PVT) measures|THC pharmacokinetics of occasional and chronic users over 24 hours|24 hoursTHC pharmacokinetics (AUC, T1 / 2, CMAX) and its relationships with genotype CYP2C9 * 3\n\nhttp://ClinicalTrials.gov/show/NCT02061020\n\n93\n\n92NCT01394185\n\nEffects of Dronabinol (Oral THC) on Cannabis Use\n\nCompleted\n\nNo Results Available\n\nMarijuana Smoking\n\nDrug: Dronabinol|Drug: Placebo\n\nJohns Hopkins University|National Institute on Drug Abuse (NIDA)\n\nBothAdult|SeniorPhase 1|Phase 225Other|NIHInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Subject, Outcomes Assessor)\n\nNA_00041251|R01DA025044\n\nJuly 12, 2011February 2011September 2012\n\nSeptember 11, 2012\n\nSeptember 2012\n\nNo Study Results Posted\n\nnullSeptember 2012\n\nMarijuana self-administration|Drug effect|Vitals\n\nhttp://ClinicalTrials.gov/show/NCT01394185\n\n94\n\n93NCT01439828\n\nClinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal\n\nNot yet recruiting\n\nNo Results Available\n\nCannabis Dependence|Cannabis Abuse\n\nDrug: N-acetylcystein\n\nAssistance Publique - Hôpitaux de Paris\n\nBothAdultPhase 2150OtherInterventional\n\nAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)\n\nP081120\n\nSeptember 21, 2011\n\nFebruary 2012February 2015January 18, 2012January 2012\n\nNo Study Results Posted\n\nMUCOCRAVFebruary 2012\n\nSuccess rate of withdrawal defined by a reduction of at least 50% of the rate of urinary carboxy-THC|The success rate of withdrawal defined by a declarative reduction of at least 50% of the cannabis|The retention rate of withdrawal|The rate of complete cessation of cannabis use|Phenotypic profile (3 major types)\n\nhttp://ClinicalTrials.gov/show/NCT01439828\n\n95\n\n94NCT00254761\n\nEffects of Smoked Marijuana on Neuropathic Pain\n\nCompleted\n\nNo Results Available\n\nNeuropathic Pain\n\nDrug: Cannabis\n\nCenter for Medicinal Cannabis Research\n\nBothAdult|SeniorPhase 1|Phase 228OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nC02-DA-114\n\nNovember 15, 2005\n\nNovember 2003February 2006\n\nFebruary 27, 2008\n\nFebruary 2008\n\nNo Study Results Posted\n\nnullFebruary 2006\n\nScore on a series of pain scales (heat pain threshold, VAS intensity, VAS unpleasantness, pain relief, neuropathic pain scale).|Number of subjects who are unable to tolerate the high dose without significant side effects.|Changes in mood, cognitive impairment, and psychomotor performance (mood - VAS happiness, cognition - Digit Symbol Modalities Test, psychomotor performance - Grooved Pegboard Test).\n\nhttp://ClinicalTrials.gov/show/NCT00254761\n\n96\n\n95NCT00781001\n\nEfficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy\n\nCompleted\n\nNo Results Available\n\nPainful Diabetic Neuropathy\n\nDrug: Cannabis\n\nCenter for Medicinal Cannabis Research\n\nBothAdult|SeniorPhase 1|Phase 217OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)\n\nC06-SD-118\n\nOctober 24, 2008\n\nJuly 2008June 2011July 29, 2013July 2013\n\nNo Study Results Posted\n\nnullJune 2011\n\nSpontaneous Pain Score|Acute sensory threshold|Experimental pain score|Cognitive testing|Subjective highness|Adverse events\n\nhttp://ClinicalTrials.gov/show/NCT00781001\n\n97\n\n96NCT01071616\n\nOral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis\n\nCompleted\n\nNo Results Available\n\nCannabis Use|Drug Abuse\n\nDrug: Cannabis Cigarette\n\nNational Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)\n\nBothAdultPhase 150NIHInterventional\n\nAllocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label\n\n999910458|10-DA-N458\n\nFebruary 18, 2010\n\nJanuary 2010November 2013March 14, 2014November 2013\n\nNo Study Results Posted\n\nnullnull\n\nTHC and metabolite concentrations in whole blood, plasma, and oral fluid, stability of these concentrations over time, performance on neurocognitive tasks and subjective assessments.\n\nhttp://ClinicalTrials.gov/show/NCT01071616\n\n98\n\n97NCT01170260\n\nAlcohol, Marijuana, and Risky Sex: Group Interventions With Detained Adolescents\n\nRecruiting\n\nNo Results Available\n\nRisk Reduction Behavior|Health Behavior|Sexual Behavior|Adolescent Behavior|Cannabis\n\nBehavioral: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Behavioral: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Behavioral: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION\n\nUniversity of New Mexico|National Institute on Alcohol Abuse and Alcoholism (NIAAA)\n\nBothChild|Adult520Other|NIHInterventional\n\nAllocation: Randomized|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)\n\nNIAAA RO1 AA013844-05|RO1 AA013844-05\n\nJuly 23, 2010August 2010June 2014August 16, 2011August 2011\n\nNo Study Results Posted\n\nMARSJune 2014\n\nTime-Line Follow-Back|Computer questionnaire\n\nhttp://ClinicalTrials.gov/show/NCT01170260\n\n99\n\n98NCT00484302\n\nSpecialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis\n\nCompleted\n\nNo Results Available\n\nMarijuana Abuse|Psychotic Disorders|Schizophrenia\n\nBehavioral: Cognitive behavioral therapy with motivational interviewing|Behavioral: Non-manualized standard treatment\n\nBispebjerg Hospital|Copenhagen Trial Unit, Center for Clinical Intervention Research|Sygekassernes Helsefond|Københavns Kommune|Lundbeck Foundation|Psychiatric Center Copenhagen\n\nBothAdult103OtherInterventional\n\nAllocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Investigator, Outcomes Assessor)\n\nCapOpusJune 6, 2007September 2007January 2011January 24, 2011January 2011\n\nNo Study Results Posted\n\nCapOpusJanuary 2011\n\nNumber of cannabis-abstinent days in past month|Psychotic symptoms|Cognitive functioning|Social functioning|Quality of life|Client satisfaction|Cost of treatment\n\nhttp://ClinicalTrials.gov/show/NCT00484302"
    }
}